GlassScriptPhysician profile
Michael L Krueger
NPI 1396714937
$6,033.63
in general payments reported to CMS, 2019-2025
33 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $382 · 2021: $591 · 2022: $756 · 2023: $939 · 2024: $1,080 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,957 · Travel and Lodging: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,956.72 |
| Travel and Lodging | $890.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,144.75 | 2019-2025 | Aveir, Gallant, Confirm Rx |
| Amgen INC. | $1,027.83 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $677.52 | 2021-2025 | |
| Pfizer INC. | $253.81 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $225.44 | 2019-2021 | |
| Cvrx, INC. | $223.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $181.77 | 2021-2025 | Verquvo |
| Cardiva Medical, INC. | $161.34 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Optowire |
| Boston Scientific Corporation | $140.38 | 2020-2025 | Watchman Flx, Farapulse |
| Abiomed | $139.16 | 2021-2022 | |
| Shockwave Medical, INC | $128.30 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $125.88 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $70.72 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.44 | 2023-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $54.61 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $52.85 | 2020-2022 | |
| Scpharmaceuticals INC. | $37.64 | 2025 | |
| Elutia, INC. | $36.62 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $34.23 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.67 | 2019-2022 | |
| Gilead Sciences, INC. | $29.69 | 2019 | |
| Astellas Pharma US INC | $23.88 | 2022 | |
| Inspire Medical Systems, INC. | $20.44 | 2023 | Inspire |
| Regeneron Healthcare Solutions, INC. | $20.13 | 2023 | Praluent, Evkeeza |
| Medtronic Vascular, INC. | $20.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.13 | 2022 | |
| Infobionic, INC | $15.96 | 2020 | |
| Novo Nordisk INC | $15.64 | 2023 | |
| Irhythm Technologies, INC. | $15.29 | 2024 | Zio Xt Patch, Zio Monitor |
| Daiichi Sankyo INC. | $14.57 | 2023 | Injectafer |
| Tactile Systems Technology INC | $14.02 | 2021 | |
| Medtronic, INC. | $12.19 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Krueger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.